

This article was downloaded by:

On: 28 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Phosphorus, Sulfur, and Silicon and the Related Elements

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713618290>

SYNTHESIS OF HETEROCYCLES ON THE BASIS OF ARYLATION PRODUCTS OF UNSATURATED COMPOUNDS. 11.¹ 5-R-BENZYL-2-IMINOSELENAZOLIDIN-4-ONES FROM ETHYL 3-ARYL-2-BROMOPROPANOATES

Mykola D. Obushak^a; Vasyl S. Matychuk^a; Volodymyr M. Tsyalkovsky^a; Roman M. Voloshchuk^a

^a Department of Organic Chemistry, Ivan Franko National University of Lviv, Lviv, Ukraine

Online publication date: 11 August 2010

To cite this Article Obushak, Mykola D. , Matychuk, Vasyl S. , Tsyalkovsky, Volodymyr M. and Voloshchuk, Roman M.(2004) 'SYNTHESIS OF HETEROCYCLES ON THE BASIS OF ARYLATION PRODUCTS OF UNSATURATED COMPOUNDS. 11.¹ 5-R-BENZYL-2-IMINOSELENAZOLIDIN-4-ONES FROM ETHYL 3-ARYL-2-BROMOPROPANOATES', Phosphorus, Sulfur, and Silicon and the Related Elements, 179: 1, 107 — 113

To link to this Article: DOI: 10.1080/10426500490257096

URL: <http://dx.doi.org/10.1080/10426500490257096>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

SYNTHESIS OF HETEROCYCLES ON THE BASIS OF ARYLATION PRODUCTS OF UNSATURATED COMPOUNDS. 11.¹ 5-R-BENZYL-2-IMINOSELENAZOLIDIN-4-ONES FROM ETHYL 3-ARYL-2-BROMOPROPANOATES

Mykola D. Obushak, Vasyl S. Matiychuk, Volodymyr M. Tsyalkovsky, and Roman M. Voloshchuk
Department of Organic Chemistry, Ivan Franko National University of Lviv, Lviv, Ukraine

(Received June 2, 2003; accepted July 27, 2003)

Ethyl 3-aryl-2-bromopropanoates 2a–p were prepared by reaction of ethyl acrylate with arenediazonium bromides 1a–p in the presence of CuBr (Meerwein arylation). These compounds react with selenourea to form 5-R-benzyl-2-iminoselenazolidin-4-ones 4a–p. Compounds 4a–p hydrolyze into the corresponding selenazolidin-2,4-diones.

Keywords: 2-iminoselenazolidin-4-one; cyclization; Meerwein arylation; selenazole; selenazolidin-2,4-dione; selenourea


Organoselenium compounds permanently attract attention of chemists; this may be conditioned on their interesting reactivities and potential pharmaceutical significance. A special place among these compounds take selenium-containing heterocycles.

Much of the interest in synthesis of selenazole derivatives is due to their biological activities.^{2–6} A convenient method to obtain the substituted selenazoles is the interaction between α -haloketones with compounds containing a selenoamide fragment— $\text{H}_2\text{NC}(\text{Se})\text{R}$.^{2,3,7–14} The interaction of these compounds with α -halogenocarboxylic acids and their derivatives to yield selenazolidin-4-ones have been studied considerably less.^{15,16}

We suggest an approach to synthesis of selenazolidin-4-one derivatives through the products of Meerwein arylation of acrylates. Arenediazonium bromides **1a–p** react with ethyl acrylate in acetone in the

Address correspondence to Mykola D. Obushak, Department of Organic Chemistry, Ivan Franko National University of Lviv, Kyryla & Mefodiya 6, Lviv 79005, Ukraine. E-mail: obushak@in.lviv.ua

presence of CuBr yielding ethyl 3-aryl-2-bromopropanoates **2a-p** (Scheme 1). We have reported the synthesis of similar compounds earlier.¹⁷ They are obtained in 40–60% yield.




2	a	b	c	d	e	f	g	h	i	j
R	H	2-Me	3-Me	4-Me	4-Et	4-Bu	4-F	2-Cl	4-Cl	4-Br

2	k	l	m	n	o	p
R	3-NO ₂	4-COOEt	4-MeO	2,3-Cl ₂	2,5-Cl ₂	3-Cl-4-Me

SCHEME 1

It has been established that esters **2a-p** react with selenourea forming selenazole rings. Selenourea alkylated by α -bromoesters while boiling in ethanol in the presence of pyridine, affords selenouronium salts **3a-p**. Under the conditions of reaction they have cyclized to give 5-R-benzyl-2-iminoselenazolidin-4-ones **4a-p** in high yields (Scheme 2).



SCHEME 2


It is necessary to stress, that the compounds **2a-p** in the presence of bases can eliminate HBr forming cinnamic esters. However, under the given conditions we can escape such a reaction.

In this reaction selenourea is more efficient than thiourea:¹⁷ reaction times are up 20–30 min and 2–3 h respectively.

Compounds of this type are characterized by imino-amino tautomerism.¹⁶ According to ^1H NMR spectra in $\text{DMSO}-d_6$ compounds **4a–p** exist in imino form (two signals of NH groups app. ~ 8.5 and ~ 9.0 ppm).

The described method of designing a selenazolidine cycle is the first which gives the opportunity to obtain selenazole derivatives containing benzyl substituents. Besides, the availability of an amidine fragment makes it possible to utilize these compounds as reagents in reactions of various types.

Thus, the performed research demonstrated the possibility to obtain 5-R-benzyl substituted selenazoles through the products of bromoarylation of acrylates. Selenazoles **4a–p** can be easily transformed into the corresponding selenazolidin-1,4-diones.



SCHEME 3

The prepared compounds seem to be interesting for biological activity studies. It is worth mentioning that among 5-R-benzylthiazolidin-4-ones a range of antidiabetic agents is known.^{18,19}

EXPERIMENTAL

All melting points are uncorrected. The ^1H NMR spectra were recorded on a Bruker 400 MHz (compounds **4c,e,i,k,m,p; 5a,b**) or Bruker DRX 500 MHz (compounds **4a,b,d,f–h,g,l,n,o**) spectrometers in $\text{DMSO}-d_6$. Chemical shifts are reported in ppm relative to the residual signal of the solvent. Coupling constants (J) are indicated in Hz. Mass spectra were obtained using a Finnigan MAT INKOS-50 chromatomass spectrometer at 70 eV.

General Procedure for the Synthesis of Ethyl 3-Aryl-2-bromopropanoates (**2a–p**)

A solution of NaNO_2 (16.6 g, 0.24 mmol) in H_2O (30 ml) was added dropwise to a stirred and ice-cooled mixture of the substituted aniline (0.22 mmol), aqueous HBr (47%, 95 g, 0.55 mmol), and water (30 ml)

below 0–5°C. The cold diazonium salt solution is slowly added to the vigorously stirred solution of CuBr (3 g, 21 mmol) and ethyl acrylate (22.0 g, 0.22 mmol) in acetone (150 ml) at 40°C. The reaction is exothermic and the dropping rate is adjusted at such a rate that nitrogen is evolved at 2–3 bubbles/sec (0.5–1 h). The resultant homogeneous solution is stirred for 30 min at 40°C and diluted with H₂O. The organic phase is dried with MgSO₄, and concentrated. The residue is purified by distillation under reduced pressure to give ethyl 3-aryl-2-bromopropanoates (40–60% yield).

General Procedure for the Synthesis of 5-R-benzyl-2-iminoselenazolidin-4-ones (4a–p)

A mixture of **2a–p** (4.1 mmol), pyridine (0.32 g, 4.1 mmol), selenourea (0.5 g, 4.1 mmol), and ethanol (15 ml) was refluxed for 20–30 min. After cooling, the crystals were collected by filtration and recrystallized from EtOH/DMF to give the title compounds.

5-Benzyl-2-iminoselenazolidin-4-one (4a). m.p. 202–203°C in 80% yield. ¹H NMR ppm: δ 2.95 (dd, 1H, CH₂, ²J 14.0, ³J 11.0), 3.64 (dd, 1H, CH₂, ³J 3.7), 4.67 (dd, 1H, CH), 7.16–7.28 (m, 5H, C₆H₅), 8.53 (s, 1H, =NH), 8.92 (br. s, 1H, NH). Anal. requires for C₁₀H₁₀N₂OSe (253.16) calcd./found: C, 47.44/47.29; H, 3.98/3.93; N, 11.07/11.03.

5-(2-Methylbenzyl)-2-iminoselenazolidin-4-one (4b). m.p. 208–210°C in 66% yield. ¹H NMR ppm: δ 2.38 (s, 3H, CH₃), 2.93 (dd, 1H, CH₂, ²J 14.7, ³J 11.6), 3.72 (dd, 1H, CH₂, ³J 3.7), 4.65 (dd, 1H, CH), 7.06–7.17 (m, 4H, C₆H₄), 8.55 (s, 1H, =NH), 8.95 (br. s, 1H, NH). Anal. requires for C₁₁H₁₂N₂OSe (267.19) calcd./found: C, 49.45/49.38; H, 4.53/4.45; N, 10.48/10.59.

5-(3-Methylbenzyl)-2-iminoselenazolidin-4-one (4c). m.p. 181–182°C in 75% yield. ¹H NMR ppm: δ 2.31 (s, 3H, CH₃), 2.87 (dd, 1H, CH₂, ²J 14.0, ³J 11.2), 3.58 (dd, 1H, CH₂, ³J 3.6), 4.70 (dd, 1H, CH), 6.98–7.04 (m, 3H, C₆H₄), 7.15 (t, 1H, C₆H₄), 8.71 (s, 1H, =NH), 9.08 (br. s, NH; exchangeable). Anal. requires for C₁₁H₁₂N₂OSe (267.19) calcd./found: C, 49.45/49.57; H, 4.53/4.51; N, 10.48/10.40.

5-(4-Methylbenzyl)-2-iminoselenazolidin-4-one (4d). m.p. 207°C in 73% yield. ¹H NMR ppm: δ 2.31 (s, 3H, CH₃), 2.91 (dd, 1H, CH₂, ²J 14.1, ³J 10.8), 3.60 (dd, 1H, CH₂, ³J 3.9), 4.64 (dd, 1H, CH), 7.05 (d, 2H, C₆H₄, ³J 7.2), 7.10 (d, 2H, C₆H₄), 8.52 (s, 1H, =NH), 8.90 (br. s, 1H, NH). Anal. requires for C₁₁H₁₂N₂OSe (267.19) calcd./found: C, 49.45/49.31; H, 4.53/4.49; N, 10.48/10.45.

5-(4-Ethylbenzyl)-2-iminoselenazolidin-4-one (4e). m.p. 184–185°C in 75% yield. ¹H NMR ppm: δ 1.21 (t, 3H, CH₃), 2.59 (q, 2H, CH₂), 2.89 (dd, 1H, CH₂, ²J 14.4, ³J 10.8), 3.57 (dd, 1H, CH₂, ³J 4.0), 4.70 (dd,

1H, CH), 7.09 (d, 2H, C₆H₄, ³J 8.4), 7.12 (d, 2H, C₆H₄), 8.77 (br. s, NH; exchangeable). Anal. requires for C₁₂H₁₄N₂OSe (281.21) calcd./found: C, 51.25/51.18; H, 5.02/4.91; N, 9.96/9.89.

5-(4-Butylbenzyl)-2-iminoselenazolidin-4-one (4f). m.p. 195°C in 80% yield. ¹H NMR ppm: δ 0.94 (t, 3H, CH₃), 1.36 (m, 2H, CH₂), 1.59 (m, 2H, CH₂), 2.56 (t, 2H, CH₂), 2.90 (dd, 1H, CH₂, ²J 14.0, ³J 10.8), 3.62 (dd, 1H, CH₂, ³J 3.7), 4.63 (dd, 1H, CH), 7.05 (d, 2H, C₆H₄, ³J 7.9), 7.11 (d, 2H, C₆H₄, ³J 7.9), 8.54 (s, 1H, =NH), 8.95 (br. s, 1H, NH). Anal. requires for C₁₄H₁₈N₂OSe (309.27) calcd./found: C, 54.37/54.23; H, 5.87/5.82; N, 9.06/9.11.

5-(4-Fluorobenzyl)-2-iminoselenazolidin-4-one (4g). m.p. 189–191°C in 78% yield. ¹H NMR ppm: δ 3.00 (dd, 1H, CH₂, ²J 14.4, ³J 7.6), 3.58 (dd, 1H, CH₂, ³J 4.4), 4.68 (dd, 1H, CH), 7.03–7.09 (m, 2H, C₆H₄), 7.24–7.29 (m, 2H, C₆H₄), 8.63 (br. s, NH; exchangeable). Anal. requires for C₁₀H₉FN₂OSe (271.15) calcd./found: C, 44.30/44.20; H, 3.35/3.27; N, 10.33/10.24.

5-(2-Chlorobenzyl)-2-iminoselenazolidin-4-one (4h). m.p. 193–194°C in 83% yield. ¹H NMR ppm: δ 3.07 (dd, 1H, CH₂, ²J 14.4, ³J 10.5), 3.80 (dd, 1H, CH₂, ³J 3.6), 4.78 (dd, 1H, CH), 7.18–7.26 (m, 2H, C₆H₄), 7.31 (d, 1H, C₆H₄), 7.35 (d, 1H, C₆H₄), 8.60 (s, 1H, =NH), 9.02 (br. s, 1H, NH). Anal. requires for C₁₀H₉ClN₂OSe (287.60) calcd./found: C, 41.76/41.84; H, 3.15/3.20; N, 9.74/9.63.

5-(4-Chlorobenzyl)-2-iminoselenazolidin-4-one (4i). m.p. 208–209°C in 74% yield. ¹H NMR ppm: δ 2.98 (dd, 1H, CH₂, ²J 14.4, ³J 10.0), 3.54 (dd, 1H, CH₂, ³J 4.4), 4.74 (dd, 1H, CH), 7.23 (d, 2H, C₆H₄, ³J 8.0), 7.28 (d, 2H, C₆H₄), 8.69 (s, 1H, =NH), 9.07 (br. s, 1H, NH). Anal. requires for C₁₀H₉ClN₂OSe (287.60) calcd./found: C, 41.76/41.63; H, 3.15/3.07; N, 9.74/9.71.

5-(4-Bromobenzyl)-2-iminoselenazolidin-4-one (4j). m.p. 196–198°C in 78% yield. ¹H NMR ppm: δ 2.99 (dd, 1H, CH₂, ²J 14.3, ³J 10.4), 3.56 (dd, 1H, CH₂, ³J 3.7), 4.67 (dd, 1H, CH), 7.17 (d, 2H, C₆H₄), 7.40 (d, 2H, C₆H₄), 8.60 (s, 1H, =NH), 8.95 (br. s, 1H, NH). Mass: (70 eV) *m/z* (%): 334 (M⁺ + 2, 18), 332 (M⁺, 24), 330 (11), 211 (39), 209 (40), 183 (54), 182 (30), 181 (28), 180 (18), 179 (12), 171 (100), 169 (98), 103 (25), 102 (48), 101 (10), 91 (22), 90 (40), 89 (32), 80 (11). Anal. requires for C₁₀H₉BrN₂OSe (332.06) calcd./found: C, 36.17/36.09; H, 2.73/2.79; N, 8.44/8.55.

5-(3-Nitrobenzyl)-2-iminoselenazolidin-4-one (4k). m.p. 205–206°C in 84% yield. ¹H NMR ppm: δ 3.22 (dd, 1H, CH₂, ²J 14.4, ³J 8.8), 3.62 (dd, 1H, CH₂, ³J 4.4), 4.85 (dd, 1H, CH), 7.57 (t, 1H, C₆H₄), 7.68 (d, 1H, C₆H₄, ³J 7.6), 8.08 (d, 1H, C₆H₄, ³J 8.0), 8.10 (s, 1H, C₆H₄), 8.70 (s, 1H, =NH), 9.08 (br. s, 1H, NH). Anal. requires for C₁₀H₉N₃O₃Se (298.16) calcd./found: C, 40.28/40.04; H, 3.04/3.01; N, 14.09/14.12.

5-(4-Ethyloxybenzyl)-2-iminoselenazolidin-4-one (4l). m.p. 197–198°C in 65% yield. ^1H NMR ppm: δ 1.38 (t, 3H, CH_3), 3.08 (dd, 1H, CH_2 , ^2J 14.0, ^3J 10.4), 3.68 (dd, 1H, CH_2 , ^3J 3.7), 4.32 (q, 2H, CH_2), 4.73 (dd, 1H, CH), 7.34 (d, 2H, C_6H_4 , ^3J 7.9), 7.90 (d, 2H, C_6H_4 , ^3J 8.5), 8.70 (br. s, NH; exchangeable). Anal. requires for $\text{C}_{13}\text{H}_{14}\text{N}_2\text{O}_3\text{Se}$ (325.22) calcd./found: C, 48.01/47.94; H, 4.34/4.27; N, 8.61/8.50.

5-(4-Methoxybenzyl)-2-iminoselenazolidin-4-one (4m). m.p. 188–189°C in 68% yield. ^1H NMR ppm: δ 2.88 (dd, 1H, CH_2 , ^2J 14.0, ^3J 10.8), 3.51 (dd, 1H, CH_2 , ^3J 4.0), 3.74 (s, 3H, CH_3), 4.70 (dd, 1H, CH), 6.80 (d, 2H, C_6H_4 , ^3J 8.4), 7.12 (d, 2H, C_6H_4), 8.67 (s, 1H, =NH), 9.03 (br. s, 1H, NH). Anal. requires for $\text{C}_{11}\text{H}_{12}\text{N}_2\text{O}_2\text{Se}$ (283.19) calcd./found: C, 46.66/46.49; H, 4.27/4.22; N, 9.89/9.99.

5-(2,3-Dichlorobenzyl)-2-iminoselenazolidin-4-one (4n). m.p. 204–206°C in 67% yield. ^1H NMR ppm: δ 3.15 (dd, 1H, CH_2 , ^2J 14.0, ^3J 10.4), 3.83 (dd, 1H, CH_2 , ^3J 4.3), 4.76 (dd, 1H, CH), 7.23 (t, 1H, C_6H_3), 7.28 (d, 1H, C_6H_3 , ^3J 7.3), 7.41 (d, 1H, C_6H_3 , ^3J 7.9), 8.63 (s, 1H, =NH), 9.03 (br. s, 1H, NH). Mass: (70 eV) m/z (%): 324 ($\text{M}^+ + 2$, 1.3), 322 (M^+ , 2), 320 (0.8), 289 (24), 287 (58), 285 (28), 219 (40), 217 (100), 215 (49), 182 (28), 161 (35), 159 (57), 136 (21), 102 (21), 89 (25), 75 (25). Anal. requires for $\text{C}_{10}\text{H}_8\text{Cl}_2\text{N}_2\text{OSe}$ (322.05) calcd./found: C, 37.30/37.29; H, 2.50/2.50; N, 8.70/8.70.

5-(2,5-Dichlorobenzyl)-2-iminoselenazolidin-4-one (4o). m.p. 217–218°C in 72% yield. ^1H NMR ppm: δ 3.10 (dd, 1H, CH_2 , ^2J 14.7, ^3J 10.4), 3.75 (dd, 1H, CH_2 , ^3J 4.3), 4.76 (m, 1H, CH), 7.23 (dd, 1H, C_6H_3 , ^3J 8.6, ^4J 1.2), 7.33–7.37 (m, 2H, C_6H_3), 8.59 (s, 1H, =NH), 9.00 (br. s, 1H, NH). Anal. requires for $\text{C}_{10}\text{H}_8\text{Cl}_2\text{N}_2\text{OSe}$ (322.05) calcd./found: C, 37.30/37.18; H, 2.50/2.42; N, 8.70/8.82.

5-(3-Chloro-4-methylbenzyl)-2-iminoselenazolidin-4-one (4p). m.p. 196°C in 70% yield. ^1H NMR ppm: δ 2.31 (s, 3H, CH_3), 2.95 (dd, 1H, CH_2 , ^2J 14.0, ^3J 10.0), 3.51 (dd, 1H, CH_2 , ^3J 4.0), 4.74 (dd, 1H, CH), 7.07 (dd, 1H, C_6H_3 , ^3J 8.0, ^4J 1.4), 7.20 (d, 1H, C_6H_3 , ^3J 8.0), 7.23 (d, 1H, C_6H_3 , ^4J 1.4), 8.73 (s, 1H, =NH), 9.10 (br. s, NH; exchangeable). Anal. requires for $\text{C}_{11}\text{H}_{11}\text{ClN}_2\text{OSe}$ (301.64) calcd./found: C, 43.80/43.71; H, 3.68/3.58; N, 9.29/9.33.

General Procedure for the Synthesis of 5-R-benzylselenazolidin-1,4-diones (5a,b)

A mixture of 5-R-benzyl-2-iminoselenazolidin-4-one (6.0 mmol) in concentrated hydrochloric acid (15 ml) was refluxed for 3 h and cooled. The crystals were collected by filtration, washed several times with water, and recrystallized from EtOH/DMF to give the title compounds.

5-(4-Fluorobenzyl)selenazolidin-1,4-dione (**5a**). m.p. 209–211°C in 42% yield. ^1H NMR ppm: δ 3.23 (dd, 1H, CH_2 , ^2J 14.4, ^3J 7.6), 3.50 (dd, 1H, CH_2 , ^3J 4.4), 4.91 (dd, 1H, CH), 7.02–7.09 (m, 2H, C_6H_4), 7.23–7.30 (m, 2H, C_6H_4), 11.27 (br. s, NH; exchangeable). Anal. requires for $\text{C}_{10}\text{H}_8\text{FNO}_2\text{Se}$ (272.14) calcd./found: C, 44.14/43.90; H, 2.96/2.88; N, 5.15/5.19.

5-(3-Chloro-4-methylbenzyl)selenazolidin-1,4-dione (**5b**). m.p. 202–203°C in 38% yield. ^1H NMR ppm: δ 2.31 (s, 3H, CH_3), 3.20 (dd, 1H, CH_2 , ^2J 14.4, ^3J 7.6), 3.47 (dd, 1H, CH_2 , ^3J 4.8), 4.92 (dd, 1H, CH), 7.09 (d, 1H, C_6H_3 , ^3J 7.6), 7.23 (d, 1H, C_6H_3), 7.27 (s, 1H, C_6H_3), 11.28 (br. s, NH; exchangeable). Anal. requires for $\text{C}_{11}\text{H}_{10}\text{ClNO}_2\text{Se}$ (302.62) calcd./found: C, 43.66/43.59; H, 3.33/3.40; N, 4.63/4.56.

REFERENCES

- [1] N. D. Obushak, V. S. Matiyshuk, and R. Ya. Vasylyshyn, *Russ. J. Org. Chem.* (in press).
- [2] V. P. Litvinov and V. D. Diachenko, *Russ. Chem. Rev.*, **66**(11), 923 (1997).
- [3] R. Larsen, *1,3-Selenazoles*, in *Comprehensive Heterocyclic Chemistry II*, edited by A. Katritzky, C. W. Rees, E. F. V. Scriven Eds. (Elsevier Science, Oxford, 1996), vol. 3, chap. 8.
- [4] D. K. Klayman and W. W. H. Gunther, eds. *Organic Selenium Compounds: Their Chemistry and Biology* (Wiley, New York, 1973), p. 663.
- [5] Y. Kumar, R. Green, D. S. Wise, L. L. Wotring, and L. B. Townsend, *J. Med. Chem.*, **36**, 3843 (1993).
- [6] Y. Kumar, R. Green, D. S. Wise, L. L. Wotring, and L. B. Townsend, *J. Med. Chem.*, **36**, 3849 (1993).
- [7] R. N. Hanson and M. A. Davis, *J. Heterocycl. Chem.*, **18**, 205 (1981).
- [8] A. Shafiee, M. A. Ebrahimzadeh, and A. Maleki, *J. Heterocycl. Chem.*, **36**(4), 901 (1999).
- [9] R. N. Hanson, *J. Heterocycl. Chem.*, **21**(1), 57 (1984).
- [10] L.-L. Lai and D. H. Reid, *Synthesis*, 870 (1993).
- [11] Bo Liu, C. Xu, and X. Zhou, *Huaxue Shiji (Chem. Reagents)*, **15**, 334 (1993); *Chem. Abstr.*, **121**, 57594t (1994).
- [12] H. M. Hassaneen, A. M. Farad, M. S. Algharib, and A. S. Shawali, *Org. Prep. Proc. Int.*, **20**, 505 (1988).
- [13] S. Bilinski, L. Bielak, J. Chmielewski, B. Marcewicz-Rojewska, and J. Musik, *Acta Pol. Pharm.*, **46**, 219 (1989).
- [14] M. F. Utinan, R. E. Valter, and G. A. Karlivan, *Chem. Heterocycl. Compd.*, **25**(10), 1201 (1989).
- [15] A. M. Comrie, D. Dingwall, and J. B. Stenlake, *J. Chem. Soc.*, 5713 (1963).
- [16] M. Koketsu, Y. Takenaka, and H. Ishihara, *Synthesis*, 731 (2001).
- [17] N. D. Obushak, V. S. Matiyshuk, and N. I. Ganushchak, *Russ. J. Org. Chem.*, **34**(2), 239 (1998).
- [18] B. B. Lohray, V. Bhushan, A. S. Reddy, et al., *J. Med. Chem.*, **42**, 2569 (1999).
- [19] A. A. Parulkar, M. L. Pendergrass, R. Granda-Ayala, T. R. Lee, and V. A. Fonseca, *Ann. Intern. Med.*, **134**, 61 (2001).